We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights

MedXY Editorial Team•Dec 1, 2025•news
esophageal squamous cell carcinomaneoadjuvant immunotherapypembrolizumabTumor Microenvironment

Highlights

– PALACE‑2 (multi‑center phase 1/2) evaluated preoperative pembrolizumab added to standard chemoradiotherapy (PPCT) in 143 patients with histologically confirmed, locally advanced, resectable esophageal squamous cell carcinoma (ESCC).

– Among 125 patients who underwent esophagectomy, pathologic complete response (pCR) was 43.2% (54/125); during neoadjuvant therapy 75.7% (106/140) experienced grade ≥3 adverse events (AEs).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Balancing Efficacy and Safety: Neoadjuvant Immunochemoradiotherapy vs. Immunochemotherapy in Elderly Esophageal Squamous Cell CarcinomaIn elderly patients with locally advanced esophageal squamous cell carcinoma, neoadjuvant immunochemoradiotherapy offers superior tumor response but increases surgical complexity and cardiac risks compared to immunochemotherapy. PersonalizeSep 15, 2026Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical TrialFive-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.Sep 15, 2026Unveiling the Molecular Evolution from Primary Gastric Cancer to Peritoneal Metastases: Implications for Targeted Surgical OncologyThis study elucidates transcriptomic differences between primary gastric cancers and peritoneal metastases, revealing distinct tumor microenvironments and molecular pathways, highlighting potential targets for improved diagnosis and therapySep 5, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Achalasia and Its Differential Impact on Esophageal Squamous Cell Carcinoma and Adenocarcinoma Risk: Insights from a Large Nordic Case-Control StudyA comprehensive multinational study reveals that achalasia significantly raises the risk of esophageal squamous cell carcinoma independently, while its association with adenocarcinoma is modest and largely mediated by gastroesophageal refluSep 5, 2026
Distinct Myeloid Landscapes Define Prognostic Niches in Extranodal NK/T-Cell LymphomaSpatial multimodal profiling reveals two macrophage-defined ENKTL subgroups with distinct tumor-myeloid interactions influencing prognosis and potential immunotherapy targets.Aug 30, 2026
Pembrolizumab Plus Quad-Shot Radiotherapy: A Promising Approach for Recurrent, Unresectable Head and Neck CancerA phase 2 trial shows pembrolizumab combined with low-dose quad-shot radiotherapy yields encouraging response rates and survival outcomes in recurrent, unresectable head and neck squamous cell carcinoma.Aug 21, 2026